TABLE 1. TOP 20 COUNTRIES WITH HIGHEST INCIDENCE OF OVARIAN CANCER, 2012
TABLE 2. TOP 20 COUNTRIES WITH HIGHEST INCIDENCE OF CERVICAL CANCER, 2012
TABLE 3. TOP 20 COUNTRIES WITH HIGHEST INCIDENCE OF ENDOMETRIAL CANCER, 2012
TABLE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016 - 2023 ($MILLION)
TABLE 5. CHEMOTHERAPY DRUGS MARKET, BY REGION, 2016 - 2023 ($MILLION)
TABLE 6. TARGETED THERAPY DRUGS MARKET, BY REGION, 2016 - 2023 ($MILLION)
TABLE 7. HORMONAL THERAPY DRUGS MARKET, BY REGION, 2016 - 2023 ($MILLION)
TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 9. UTERINE CANCER DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 10. DRUGS APPROVED FOR OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
TABLE 11. DRUG COMBINATIONS USED IN OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
TABLE 12. OVARIAN CANCER DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 13. INCIDENCE AND MORTALITY OF VAGINAL & VULVAR CANCERS IN U.S. (2014)
TABLE 14. DRUGS FOR TREATMENT OF VAGINAL & VULVAR CANCERS
TABLE 15. VAGINAL & VULVAR CANCER DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 16. DRUGS FOR TREATMENT OF CERVICAL CANCER
TABLE 17. CERVICAL CANCER DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. INCIDENCE RATES OF GYNECOLOGICAL CANCERS IN U.S., BY STATE, 2014
TABLE 20. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 21. U.S. GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 22. U.S. GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 23. CANADA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 24. CANADA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 25. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 26. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 27. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 28. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 29. ESTIMATED INCIDENCE AND MORTALITY OF GYNECOLOGICAL CANCERS IN EUROPE, BY COUNTRY, 2012
TABLE 30. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 31. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 32. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 33. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 34. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 35. UK GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 36. UK GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 37. ITALY GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 38. ITALY GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 39. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 40. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 41. REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 42. REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 43. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 44. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 45. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 46. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 47. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 48. CHINA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 49. CHINA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 50. INDIA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 51. INDIA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 52. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 53. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 54. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 55. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 56. REST OF ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 57. REST OF ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 58. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 59. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 60. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 61. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 62. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 63. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 64. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 65. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 66. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 67. REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 68. REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 69. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 70. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 71. APOTEX: COMPANY SNAPSHOT
TABLE 72. APOTEX: PRODUCT PORTFOLIO
TABLE 73. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 74. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 75. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 76. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 77. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 78. LILLY: COMPANY SNAPSHOT
TABLE 79. LILLY: OPERATING SEGMENTS
TABLE 80. LILLY: PRODUCT PORTFOLIO
TABLE 81. ROCHE: COMPANY SNAPSHOT
TABLE 82. ROCHE: OPERATING SEGMENTS
TABLE 83. ROCHE: PRODUCT PORTFOLIO
TABLE 84. GSK: COMPANY SNAPSHOT
TABLE 85. GSK: OPERATING SEGMENTS
TABLE 86. GSK: PRODUCT PORTFOLIO
TABLE 87. MERCK: COMPANY SNAPSHOT
TABLE 88. MERCK: OPERATING SEGMENTS
TABLE 89. MERCK: PRODUCT PORTFOLIO
TABLE 90. NOVARTIS: COMPANY SNAPSHOT
TABLE 91. NOVARTIS: OPERATING SEGMENTS
TABLE 92. NOVARTIS: PRODUCT PORTFOLIO
TABLE 93. PFIZER: COMPANY SNAPSHOT
TABLE 94. PFIZER: OPERATING SEGMENTS
TABLE 95. PFIZER: PRODUCT PORTFOLIO
TABLE 96. TEVA: COMPANY SNAPSHOT
TABLE 97. TEVA: OPERATING SEGMENTS
TABLE 98. TEVA: PRODUCT PORTFOLIO

LIST OF FIGURE

FIGURE 1. GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP PLAYER POSITIONING, 2016
FIGURE 4. CLINICAL TRIALS FOR GYNECOLOGICAL CANCER DRUGS, BY CANCER TYPE (%)
FIGURE 5. CLINICAL TRIALS FOR GYNECOLOGICAL CANCER DRUGS, BY REGION (%)
FIGURE 6. CLINICAL TRIALS FOR OVARIAN CANCER DRUGS, BY REGION (%)
FIGURE 7. CLINICAL TRIALS FOR CERVICAL CANCER DRUGS, BY REGION (%)
FIGURE 8. CLINICAL TRIALS FOR UTERINE CANCER DRUGS, BY REGION (%)
FIGURE 9. CLINICAL TRIALS FOR VAGINAL CANCER DRUGS, BY REGION (%)
FIGURE 10. CLINICAL TRIALS FOR VULVAR CANCER DRUGS, BY REGION (%)
FIGURE 11. INCIDENCE OF CERVICAL CANCER IN ASIA, 2012
FIGURE 12. COMPARISON OF THE TEN MOST FREQUENT CANCERS IN WOMEN AGED 15-44 YEARS IN ASIA, 2012
FIGURE 13. INCIDENCE OF CERVICAL CANCER IN LAMEA, 2012
FIGURE 14. ASTRAZENECA: NET SALES, 2014-2016 ($MILLION)
FIGURE 15. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 16. BRISTOL-MYERS SQUIBB: NET SALES, 2014-2016 ($MILLION)
FIGURE 17. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 18. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 19. LILLY: NET SALES, 2014-2016 ($MILLION)
FIGURE 20. LILLY: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 21. LILLY: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 22. ROCHE: NET SALES, 2014-2016 ($MILLION)
FIGURE 23. ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 24. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25. GSK: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. GSK: REVENUE SHARE BY PRODUCT, 2016 (%)
FIGURE 27. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 28. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 29. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 30. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 31. NOVARTIS: NET SALES, 2014-2016 ($MILLION)
FIGURE 32. NOVARTIS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 33. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 34. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 35. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 36. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 37. TEVA: NET SALES, 2014-2016 ($MILLION)
FIGURE 38. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 39. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)